These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18286491)

  • 1. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
    Atkinson DM; Clarke MJ; Mladek AC; Carlson BL; Trump DP; Jacobson MS; Kemp BJ; Lowe VJ; Sarkaria JN
    Head Neck; 2008 Jun; 30(6):790-9. PubMed ID: 18286491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
    Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
    Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.
    Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H
    Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
    Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
    J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-fluorodeoxythymidine micro-positron-emission tomography versus 18F-fluorodeoxyglucose micro-positron-emission tomography for in vivo minimal residual disease imaging.
    Ekshyyan O; Sibley D; Caldito GC; Sunderland J; Vascoe C; Nathan CA
    Laryngoscope; 2013 Jan; 123(1):107-11. PubMed ID: 23018799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
    Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
    Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.
    Manning HC; Merchant NB; Foutch AC; Virostko JM; Wyatt SK; Shah C; McKinley ET; Xie J; Mutic NJ; Washington MK; LaFleur B; Tantawy MN; Peterson TE; Ansari MS; Baldwin RM; Rothenberg ML; Bornhop DJ; Gore JC; Coffey RJ
    Clin Cancer Res; 2008 Nov; 14(22):7413-22. PubMed ID: 19010858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
    Sharafinski ME; Ferris RL; Ferrone S; Grandis JR
    Head Neck; 2010 Oct; 32(10):1412-21. PubMed ID: 20848399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.
    Honndorf VS; Wiehr S; Rolle AM; Schmitt J; Kreft L; Quintanilla-Martinez L; Kohlhofer U; Reischl G; Maurer A; Boldt K; Schwarz M; Schmidt H; Pichler BJ
    Oncotarget; 2016 May; 7(19):28247-61. PubMed ID: 27070087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
    van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
    Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.